The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies. 

Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to 2028.

Look out for the Evaluate Vantage Medtech World Preview, coming soon. 



The top 10 medtech players in 2028 – including who’s growing, but still falling down the leader board.
The top 10 device areas in 2028 – spoiler alert: in vitro diagnostics might be taking a post-Covid hit, but it’s still the biggest area, followed by cardiology.
R&D spend out to 2028 – and who’s likely to be getting the best bang for their buck.